Comparison Overview

Brigham and Women's Hospital

VS

Zuellig Pharma

Brigham and Women's Hospital

undefined, undefined, undefined, undefined, US
Last Update: 2025-11-20

Boston's Brigham and Women's Hospital (BWH) is an international leader in virtually every area of medicine and has been the site of pioneering breakthroughs that have improved lives around the world. A major teaching hospital of Harvard Medical School, BWH has a legacy of excellence that continues to grow. With two outstanding hospitals, over 150 outpatient practices, and over 1,200 physicians, we serve patients from New England, throughout the United States, and from 120 countries around the world. The BWH name is a reflection of our history. In 1980 three of Boston’s oldest and most prestigious Harvard Medical School teaching hospitals - the Peter Bent Brigham Hospital, the Robert Breck Brigham Hospital, and the Boston Hospital for Women – merged to form Brigham and Women’s Hospital. As a national leader in improving health care quality and safety, we have helped to develop some of the industry’s best practices including computerized physician order entry (CPOE) to prevent medication errors. The CPOE is now a nationally-accepted safety practice. The BWH Biomedical Research Institute (BRI) is one of the most powerful biomedical research institutes in the world and the second largest recipient of National Institutes of Health (NIH) funding among independent hospitals in the United States. BWH has long had great success in research as measured by the number of important discoveries made, the size and scope of its research portfolio and the volume of publications annually. BWH is a training ground for physicians, nurses, and allied health professionals. We have 1,100 trainees in over 140 of the most sought after training programs in the world, and also host Harvard Medical School students in rotations throughout our programs. As our global health services expand, our clinical trainees have rich opportunities to contribute and learn in challenging environments around the world. Brigham and Women's Hospital is an EEO, AA, VEVRAA Employer.

NAICS: 62
NAICS Definition: Health Care and Social Assistance
Employees: 15,483
Subsidiaries: 10
12-month incidents
0
Known data breaches
2
Attack type number
1

Zuellig Pharma

47 Scotts Road Goldbell Towers, #10-00 Singapore, Singapore 228233, SG
Last Update: 2025-11-21
Between 750 and 799

Zuellig Pharma is a leading integrated healthcare solutions company in Asia with experience spanning over a century in the region. Partnering with multinational pharmaceutical manufacturers, governments, healthcare providers, and professionals, we broaden access to pharmaceutical and healthcare products. This is achieved through our services across three Business Units: Distribution, Commercialization, and Clinical Trial Support. Our purpose of ‘Making Healthcare More Accessible’ is driven by our three values: upholding the highest standards of integrity and excellence, embracing a growth mindset, and collaborating for shared success.

NAICS: 62
NAICS Definition: Health Care and Social Assistance
Employees: 10,001
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/brigham-and-women's-hospital.jpeg
Brigham and Women's Hospital
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/zuellig-pharma.jpeg
Zuellig Pharma
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Brigham and Women's Hospital
100%
Compliance Rate
0/4 Standards Verified
Zuellig Pharma
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Hospitals and Health Care Industry Average (This Year)

No incidents recorded for Brigham and Women's Hospital in 2025.

Incidents vs Hospitals and Health Care Industry Average (This Year)

No incidents recorded for Zuellig Pharma in 2025.

Incident History — Brigham and Women's Hospital (X = Date, Y = Severity)

Brigham and Women's Hospital cyber incidents detection timeline including parent company and subsidiaries

Incident History — Zuellig Pharma (X = Date, Y = Severity)

Zuellig Pharma cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/brigham-and-women's-hospital.jpeg
Brigham and Women's Hospital
Incidents

Date Detected: 7/2023
Type:Breach
Blog: Blog

Date Detected: 11/2020
Type:Breach
Attack Vector: Human Error
Blog: Blog
https://images.rankiteo.com/companyimages/zuellig-pharma.jpeg
Zuellig Pharma
Incidents

No Incident

FAQ

Brigham and Women's Hospital company demonstrates a stronger AI Cybersecurity Score compared to Zuellig Pharma company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Brigham and Women's Hospital company has historically faced a number of disclosed cyber incidents, whereas Zuellig Pharma company has not reported any.

In the current year, Zuellig Pharma company and Brigham and Women's Hospital company have not reported any cyber incidents.

Neither Zuellig Pharma company nor Brigham and Women's Hospital company has reported experiencing a ransomware attack publicly.

Brigham and Women's Hospital company has disclosed at least one data breach, while the other Zuellig Pharma company has not reported such incidents publicly.

Neither Zuellig Pharma company nor Brigham and Women's Hospital company has reported experiencing targeted cyberattacks publicly.

Neither Brigham and Women's Hospital company nor Zuellig Pharma company has reported experiencing or disclosing vulnerabilities publicly.

Neither Brigham and Women's Hospital nor Zuellig Pharma holds any compliance certifications.

Neither company holds any compliance certifications.

Brigham and Women's Hospital company has more subsidiaries worldwide compared to Zuellig Pharma company.

Brigham and Women's Hospital company employs more people globally than Zuellig Pharma company, reflecting its scale as a Hospitals and Health Care.

Neither Brigham and Women's Hospital nor Zuellig Pharma holds SOC 2 Type 1 certification.

Neither Brigham and Women's Hospital nor Zuellig Pharma holds SOC 2 Type 2 certification.

Neither Brigham and Women's Hospital nor Zuellig Pharma holds ISO 27001 certification.

Neither Brigham and Women's Hospital nor Zuellig Pharma holds PCI DSS certification.

Neither Brigham and Women's Hospital nor Zuellig Pharma holds HIPAA certification.

Neither Brigham and Women's Hospital nor Zuellig Pharma holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Angular is a development platform for building mobile and desktop web applications using TypeScript/JavaScript and other languages. Prior to versions 19.2.16, 20.3.14, and 21.0.1, there is a XSRF token leakage via protocol-relative URLs in angular HTTP clients. The vulnerability is a Credential Leak by App Logic that leads to the unauthorized disclosure of the Cross-Site Request Forgery (XSRF) token to an attacker-controlled domain. Angular's HttpClient has a built-in XSRF protection mechanism that works by checking if a request URL starts with a protocol (http:// or https://) to determine if it is cross-origin. If the URL starts with protocol-relative URL (//), it is incorrectly treated as a same-origin request, and the XSRF token is automatically added to the X-XSRF-TOKEN header. This issue has been patched in versions 19.2.16, 20.3.14, and 21.0.1. A workaround for this issue involves avoiding using protocol-relative URLs (URLs starting with //) in HttpClient requests. All backend communication URLs should be hardcoded as relative paths (starting with a single /) or fully qualified, trusted absolute URLs.

Risk Information
cvss4
Base: 7.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Uncontrolled Recursion vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft deep ASN.1 structures that trigger unbounded recursive parsing. This leads to a Denial-of-Service (DoS) via stack exhaustion when parsing untrusted DER inputs. This issue has been patched in version 1.3.2.

Risk Information
cvss4
Base: 8.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Integer Overflow vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft ASN.1 structures containing OIDs with oversized arcs. These arcs may be decoded as smaller, trusted OIDs due to 32-bit bitwise truncation, enabling the bypass of downstream OID-based security decisions. This issue has been patched in version 1.3.2.

Risk Information
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. Prior to versions 7.0.13 and 8.0.2, working with large buffers in Lua scripts can lead to a stack overflow. Users of Lua rules and output scripts may be affected when working with large buffers. This includes a rule passing a large buffer to a Lua script. This issue has been patched in versions 7.0.13 and 8.0.2. A workaround for this issue involves disabling Lua rules and output scripts, or making sure limits, such as stream.depth.reassembly and HTTP response body limits (response-body-limit), are set to less than half the stack size.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. In versions from 8.0.0 to before 8.0.2, a NULL dereference can occur when the entropy keyword is used in conjunction with base64_data. This issue has been patched in version 8.0.2. A workaround involves disabling rules that use entropy in conjunction with base64_data.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H